

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Quinidine sulfate hydrate

March 17, 2026

### **Therapeutic category**

Antiarrhythmic agents

### **Non-proprietary name**

Quinidine sulfate hydrate

### **Safety measure**

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
 This English version is intended to be a reference material to provide convenience for users.  
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision											
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Amiodarone hydrochloride (injection), vardenafil hydrochloride hydrate, eliglustat tartrate, siponimod fumaric acid, fingolimod hydrochloride, toremifene citrate, voriconazole, posaconazole, moxifloxacin hydrochloride, lascufloxacin hydrochloride (injection), ritonavir, nirmatrelvir/ritonavir, ensitrelvir fumaric acid, itraconazole, fluconazole, fosfluconazole, miconazole, mefloquine hydrochloride</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Amiodarone hydrochloride (injection), vardenafil hydrochloride hydrate, eliglustat tartrate, siponimod fumaric acid, fingolimod hydrochloride, toremifene citrate, <u>ceritinib</u>, voriconazole, posaconazole, moxifloxacin hydrochloride, lascufloxacin hydrochloride (injection), ritonavir, nirmatrelvir/ritonavir, ensitrelvir fumaric acid, itraconazole, fluconazole, fosfluconazole, miconazole, mefloquine hydrochloride</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1133 970 2000 1414"> <thead> <tr> <th data-bbox="1133 970 1469 1043">Drugs</th> <th data-bbox="1473 970 1715 1043">Signs, symptoms, and treatment</th> <th data-bbox="1720 970 2000 1043">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 1046 1469 1120"></td> <td data-bbox="1473 1046 1715 1120"></td> <td data-bbox="1720 1046 2000 1120"></td> </tr> <tr> <td data-bbox="1133 1123 1469 1414"><u>Ceritinib</u></td> <td data-bbox="1473 1123 1715 1414"><u>QT prolonged, etc. may occur.</u></td> <td data-bbox="1720 1123 2000 1414"><u>The blood concentration of this drug is expected to increase because of inhibited metabolism of this drug due to inhibition of the hepatic drug metabolizing</u></td> </tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors				<u>Ceritinib</u>	<u>QT prolonged, etc. may occur.</u>	<u>The blood concentration of this drug is expected to increase because of inhibited metabolism of this drug due to inhibition of the hepatic drug metabolizing</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors										
<u>Ceritinib</u>	<u>QT prolonged, etc. may occur.</u>	<u>The blood concentration of this drug is expected to increase because of inhibited metabolism of this drug due to inhibition of the hepatic drug metabolizing</u>										

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

*This English version is intended to be a reference material to provide convenience for users.*

*In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

			<u>enzyme (CYP3A4)</u> <u>by the drugs listed</u> <u>on the left.</u>
--	--	--	---

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.